KRAS-targeted cancer vaccine shows promise Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

https://www.drugdiscoverynews.com/kras-targeted-vaccine-shows-promise-16685?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-8xwGUqNpDq2mS2DpgAZUWUKI2UyKtfs5JdKcK0-oF5-Lmf0YdiafkQtJvGieyZTdeKcn3p_ii9i0AvfwHpIjQ4Sis-_Q&_hsmi=389580236&utm_content=389580236&utm_source=hs_email